FY2026 Earnings Forecast for OVID Issued By HC Wainwright

Ovid Therapeutics Inc. (NASDAQ:OVID) – HC Wainwright issued their FY2026 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.60) for the year. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share.

Several other equities research analysts have also issued reports on OVID. BTIG Research dropped their price objective on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Monday. Wedbush reiterated an “outperform” rating and set a $3.00 price target (down previously from $4.00) on shares of Ovid Therapeutics in a research report on Wednesday, March 12th. Finally, Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a research report on Wednesday, January 29th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $3.03.

Ovid Therapeutics Stock Down 3.2 %

Shares of NASDAQ:OVID opened at $0.43 on Tuesday. The firm has a fifty day moving average price of $0.59 and a two-hundred day moving average price of $0.92. The company has a market cap of $30.58 million, a price-to-earnings ratio of -0.92 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. Ovid Therapeutics has a one year low of $0.42 and a one year high of $3.45.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.19 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%.

Hedge Funds Weigh In On Ovid Therapeutics

A number of large investors have recently modified their holdings of OVID. Takeda Pharmaceutical Co. Ltd. bought a new position in Ovid Therapeutics during the fourth quarter valued at approximately $7,012,000. Kennedy Capital Management LLC grew its holdings in shares of Ovid Therapeutics by 1.1% during the 4th quarter. Kennedy Capital Management LLC now owns 1,545,387 shares of the company’s stock valued at $1,443,000 after purchasing an additional 17,402 shares during the last quarter. Geode Capital Management LLC raised its position in Ovid Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock worth $1,555,000 after purchasing an additional 14,816 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Ovid Therapeutics in the fourth quarter worth $934,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Ovid Therapeutics by 50.2% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company’s stock valued at $881,000 after buying an additional 315,126 shares during the period. 72.24% of the stock is owned by hedge funds and other institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.